Clinical trial
Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic…
NCT00126633 · University of California, San Francisco, Other · Completed
Key facts
| NCT number | NCT00126633 |
|---|---|
| Title | Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer |
| Official title | A Study of Fixed-Dose Rate Gemcitabine, Cisplatin, and Bevacizumab in Previously Untreated Patients With Metastatic Pancreatic Cancer |
| Lead sponsor | University of California, San Francisco, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Biological, Drug |
| Interventions | bevacizumab, cisplatin, gemcitabine hydrochloride |
| Enrollment | 53 |
| Start date | Apr 1, 2004 |
| Primary completion | Sep 1, 2006 |
| Completion | Oct 1, 2008 |
| First posted | Aug 4, 2005 |
| Last update posted | Sep 17, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: